List of Vendor Companies in Switzerland - 65

1DROP saves lives through better faster near patient health monitoring. 1DROP enables personalized healthcare by providing actionable health information that is accessible to everyone everywhere. One drop of sample, a few minutes and you receive your diagnostic test results on your mobile phone. 1DROP makes this a reality: 1. 1DROP Chip, to which a drop of sample (usually blood) is applied; 2. 1DROP portable Analyser, which quantifies multiple biomarkers from the 1DROP Chip within minutes; 3. 1DROP App, which is synchronised with the 1DROP Cloud, and shares data with Electronic Health Records (EHR), streamlining clinical workflows by providing access to patient diagnostic results in real-time and anywhere.

We provide licenses for the commercial use of our software, OpenGenomeBrowser, as well as support, development and consulting services help to advance your research and discoveries.

Acino is a Swiss pharmaceutical company headquartered in Zurich, with a clear focus on high-growth markets. We deliver quality pharmaceuticals to promote affordable healthcare and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing. For more information: www.acino.swiss *** By engaging with Acino on LinkedIn (or any other Acino social media channel), you are agreeing to our Social Media Community Guidelines. If you do not agree to them, do not engage with Acino on social media. Please read our detailed community guidelines carefully here: https://acino.swiss/social-media-community-guidelines ***

Your Best Partner In Diagnostics 28 years of dedication has made us what we are today, one of the forerunners in the Indian diagnostics industry. The 2nd biggest Diagnostic Companies in India with a formidable Domestic and International presence for the entire range of Reagents and Equipment. Our Reagent range includes Biochemistry Kits, Serology Kits, Immunoturbidimetry Kits, Specialized Kits, Coagulation Reagents, Hematology Reagents and System Reagents for Fully Automated Clinical Chemistry Analyzers. We are an ISO 9001- 2008 and ISO 13485:2003 certified Company. We conform to GMP standards and have an FDA approved most modern manufacturing facility. We have been successful in obtaining CE Marking as well for all our products. We have formed a wholly owned Subsidiary Company in Switzerland called Agappe Diagnostics Switzerland GmbH to cater to the needs of the world market effectively. We are the sole distributors of companies such as Toshiba Medical Systems Corporation (Japan), Mindray (China), I-Sens (Korea) and many other giants in the diagnostic industry. Our Vision To Establish Globally As A Premier In-Vitro Diagnostic Corporation And To Be The Best Partner In The Diagnostic Field For The Welfare Of Mankind. Our Mission To Expand And Continuously Improve Our Products And Services With A World Class R&D Program And To Provide The Best Work Environment For Our Employees To Meet And Exceed Their True Potential And To Thrive In A World Of Excellence.

Developing solutions that simplify and streamline the generation of "big RNA data", which we believe will constitute the foundation of tomorrow's research and medicine.

Anjarium Biosciences is a cell and gene therapy tools and technology company headquartered in Switzerland. Our mission is to enable researchers and manufacturers to accelerate the discovery and delivery cycle of new and evolving genetic medicines. Our technology enables our partners to meet biology’s greatest challenges with increasingly flexible and customizable DNA constructs in pursuit of better human health. We offer a range of products to support research, development, and commercialization of genetic medicines. Our enzymatic, cell-free platform enables Anjarium to offer pure, infinitely customizable, stable synthetic DNA constructs at scale for use across AAV, mRNA, Lentivirus and other applications.

Aspivix is a medical device company in women’s health, based in Switzerland, developing next-generation devices for gynecology. Our flagship product, Carevix™, is the world’s first suction cervical stabilizer clinically proven to reduce pain and bleeding associated with transcervical procedures commonly performed in gynecology, including IUD insertion, hysteroscopy, cervical biopsies, fertility treatments, and more. Carevix™ is a medical device that has received in 2023 FDA-clearance for the US market, as well as the CE-Mark for the European countries. Carevix™ study published in the international journal, Contraception, in March 2023 demonstrated superiority over the use of a single tooth tenaculum, reducing the pain by up to 73% and the bleeding by up to 83% in IUD insertions. More than 120 million women worldwide have procedures using the antiquated single-tooth tenaculum, an instrument invented over a century ago, without consideration of a woman's anatomy or pain, and yet it is still considered to be the standard of care in gynecology. At Aspivix, we think women deserve more. We are driven by our vision to make gynecology modern.

Our mission is to save lives by bringing fast and actionable infectious disease diagnosis closer to the patient. Avelo's solution is a breath collection device. It works with existing molecular tests to detect multiple respiratory tract infections causing pneumonia

Bachem is a pharmaceuticals company that specializes in research chemicals, peptide synthesis, and other life sciences products.

The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented. Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making. Our Solutions We offer a versatile portfolio of proprietary proteomics services, software, and kits. We make these widely available for pharmaceutical and biotechnology researchers and proteomics experts. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all major sample types – cells, tissues, or body fluids – across human and non-human species. Our Technology Biognosys is the leading inventor and developer of mass spectrometry-based proteomics solutions. With market leading proteome coverage and sample throughput we enable simultaneous quantification of thousands of proteins across thousands of samples. Our Facility From our global headquarters just outside of Zurich, we operate one of the largest high-end mass spectrometry laboratories worldwide for Large-Scale Discovery Proteomics contract research. Our Data Competence Biognosys has analyzed a vast amount of proteomics data and developed an industry-leading understanding of the proteome. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. Global Presence Founded in 2008 as a spin-off from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys today is an established leader in next-generation proteomics. With employees based across Switzerland, Europe, and US, and an extensive network of collaborators and distributors, Biognosys supports a global customer base of life science researchers across industry and academia.

Critical Raw Materials and Services for Diagnostics, Vaccines and Pharmaceuticals. Where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. Biosynth's mission is to supply critical raw materials and services to the pharmaceutical and diagnostic industries. Biosynth strives to de-risk its customer's supply chains. Our expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Biosynth is a life sciences reagents, custom synthesis and manufacturing services company. We are by scientists, for scientists, securing supply chains with consistent quality, across the globe. We manufacture and source a vast range of chemical and biochemical products, and take pride in delivering products that others cannot. We are experts in complex chemistry, peptides and key biological raw materials. We provide a full range of products and services to support life science research and development, with more than a million products in our research catalog and hundreds of complex manufacturing service projects. The trusted supplier, manufacturer and partner for the pharmaceutical, life science and diagnostic sectors, along with customers across food, agrochemistry and cosmetics, we have facilities across three continents and a rapid global distribution network. We produce chemicals on the milligram to ton scale, and at ISO 9001 and GMP, with peptides at mg to multikilogram scale. Biosynth's services and products include enzyme development and biocatalysis, reagents for in vitro diagnostics and bioconjugation chemistry. Biosynth is owned, among others by KKR, Ampersand and Senior Management.

BioXpress Therapeutics SA is a premier provider of high-quality biologic APIs for unmet need indications, such as cancer, inflammation and autoimmunity.

Caris Life Sciences® (Caris) is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets.

Cilag manufactures pharmaceutical ingredients and pharmaceutical products.

Clinerion, a wholly owned subsidiary of TriNetX LLC, accelerates clinical research and medical access to treatments for patients. We use proprietary, patented technologies for analysis of live electronic health record (EHR) data from our global network of partner hospitals to generate real-world data (RWD), which can be used for investigation into disease epidemiology, the patient journey and outcomes, and patient care metrics. Clinerion's Patient Network Explorer platform radically improves the efficiency and effectiveness of clinical trials by offering data-driven protocol optimization, site feasibility evaluation, and search and identification for patient recruitment – in real-time. Among other uses, we provide solutions for increasing diversity in clinical trials and identification of rare disease patients. Clinerion's new Federated Machine Learning Platform enables the training and validation of machine learning (ML) algorithms on our global RWD network. Apart from the contributions to drug development this platform targets to develop preventive care for patients before they reach a critical stage. Clinerion operates on the principle of "privacy by design" and complies fully with international patient privacy and data security regulations. Clinerion is headquartered in Switzerland. Clinerion website: www.clinerion.com Clinerion's Patient Network Explorer: www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer

CovalX has been established as the leader in characterizing protein interactions by mass spectrometry. Providing Innovative Technologies and Exclusive Services, CovalX has been doing business with world-renowned Universities, therapeutic companies, and most major pharmaceutical companies worldwide for many years. CovalX AG developed a unique protocol for measuring intact protein complexes using MALDI mass spectrometry. CovalX both sells the tools and/or services for High-Mass MALDI protein-protein interaction analysis. The main applications involve: • epitope mapping (both conformational or linear) • characterizing aggregates from biotherapeutic drugs • analyzing antibody-antigen interactions • rapid characterization of any protein complexes (stoichiometry, inhibition, etc) CovalX also has flexibility and provides services for characterizing any large macro molecules such as PEGylated proteins or polymers. CovalX has recently restructured by moving some of its hardware support facilities and US sales and marketing into the US and establishing an official subsidiary in the Boston area.

CREOPTIX IS NOW A MALVERN PANALYTICAL PHARMACEUTICALS BRAND. Please follow us on this page to stay up to date > https://lnkd.in/e_UMrvip THE WAVE OF THE FUTURE IN KINETICS. Experience a new level of performance and flexibility in drug discovery. By bringing together modern label-free technology, application development know-how and sophisticated software, Creoptix offers a unique optical biosensor tool for binding kinetics. Engineered around our proprietary Grating-Coupled Interferometry (GCI) technology, the Creoptix WAVEsystem delivers high-quality kinetic data across a broader range of samples than traditional SPR equipment. Following integration in January 2022, Creoptix is a Malvern Panalytical brand. About Malvern Panalytical: We draw on the power of our analytical instruments and services to make the invisible visible and the impossible possible. Through the chemical, physical and structural analysis of materials, our high precision analytical systems and top-notch services support our customers in creating a better world. We help them improve everything from the energies that power us and the materials we build with, to the medicines that cure us and the foods we enjoy. With over 2300 employees, we serve the world, and we are part of Spectris plc, the world leading precision measurement group. Malvern Panalytical. We're BIG on small™

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!

Endeavour Vision is a leading venture capital and growth equity advisory firm focusing on commercial-stage medtech and digital health companies. We support transformative healthcare technologies that provide superior clinical benefits for patients or bring significant efficiencies to health systems. Our team offers strategic and operational expertise and extensive international experience investing in companies in Europe and North America. We have a proven track record of successful exits with recently realized investments that include Relievant Medsystems, Vertiflex, and Symetis, as well as several IPOs. Endeavour Vision’s international investment teams are located in Geneva, Switzerland, Minneapolis, US and San Francisco, US.

ender pursues a holistic approach that focuses on the health of humans, animals and the environment. Our diagnostic screening solutions and complementary services make it possible to make informed decisions at an early stage and take the necessary measures. Through this preventive approach, we help to identify and contain diseases at an early stage, reduce unnecessary suffering, open up new perspectives and enable economic and ecological solutions. As a Swiss SME, we thus make an important contribution to promoting health.

Endotelix is a privately held Swiss biotech start-up company and a spin-off from the University of Geneva. Endotelix is dedicated to providing fast, sensitive and reliable solutions for Antiphospholipid Syndrome, including diagnostic tests and therapies.

Mathys is committed to motion worldwide. Founded in 1946, the company has been active in medical technology since 1958 and focuses on the development, manufacture and distribution of joint replacement products. The company's services include implants for hip, knee, shoulder and sports orthopaedics, and synthetic bone graft substitute. Headquartered in Bettlach, Switzerland, Mathys has development and production sites in Switzerland and Germany, as well as subsidiaries in 10 countries, and has been part of the US-based company Enovis™ since 2021. Enovis is committed to measurably improving patient outcomes by developing specialised solutions to clinical problems.

For more than 45 years, Enzo Biochem has been a leader in innovation and product development to support a diverse range of needs in biomedical research and healthcare. With a comprehensive portfolio of 20,000 high-quality products including antibodies, genomic probes, assays, biochemicals, and proteins, Enzo supports the work of academic research centers and industry partners who are shaping the future of healthcare around the world. The company’s proprietary products and technologies play central roles in all areas of translational research and drug development, including genomic analysis, protein analysis, cellular analysis, tissue analysis, and small molecule chemistry. Enzo Biochem has a broad and deep intellectual property port-folio, with patent coverage across a number of key enabling technologies.

Epithelix Sàrl is a Swiss biotech company specialized in human tissue engineering. Epithelix provides innovative R&D solutions for the study of human respiratory diseases (e.g. Asthma, COPD, Cystic Fibrosis, etc.) and for inhalation toxicity testing of chemicals, while reducing the number of animal experiments.

​evitria is specialized in CHO-based transient expression of antibodies (including bispecific and fusion antibodies). With a track record of more than 120,000 successful antibody production runs for our clients, we can offer fast and reliable project execution at high quality standards (all production facilities in Switzerland). You can benefit from our expertise and unique focus when looking to entrust a partner with your complete antibody production or to manage capacity bottlenecks with single projects.

At Evolva we believe in applying technology platforms, such as fermentation, to help resolve sourcing bottlenecks in nature. These enable us to provide products that can contribute to health, wellbeing and sensory enjoyment. We research, develop and commercialize high quality, affordable, ready-to-formulate ingredients that are based on nature and are available at all times, in any quantity. With around 55 employees from 15 nationalities we promote an interdisciplinary and inclusive working environment.

Founded in 1997, Genedata delivers enterprise solutions to enable Biopharma R&D globally to discover, develop, and manufacture innovative biotherapeutics faster and more efficiently. Genedata combines computational, scientific, and technical expertise with extensive biopharma R&D domain knowledge to deliver user-friendly solutions that are scalable, open, and aligned with industry processes. Today, most of the leading pharmaceutical, biotechnology, and agrichemical companies, as well as innovative life science research institutions rely on Genedata. Genedata is proud to be part of Danaher. Danaher’s science and technology leadership puts Genedata’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

Givaudan is a global leader in Fragrance & Beauty and Taste & Wellbeing. We celebrate the beauty of human experience by creating for happier, healthier lives with love for nature. Together with our customers we deliver food experiences, craft inspired fragrances, and develop beauty and wellbeing solutions that make people look and feel good. With over 163 locations in 52 countries and over 78 production sites, of which 31 are located in Europe, 22 in North America, 17 in Latin America, 8 in Asia-Pacific, and 1 across South Asia, the Middle East, and Africa, we are committed to driving purpose-led growth that makes a positive impact. Givaudan: Human by nature. www.givaudan.com

INFORS HT is your specialist for bioreactors, incubation shakers and bioprocess control software for reliable and efficient cultivations. You benefit from sophisticated systems, in which your cell lines or microorganisms develop their full potential in a reproducible way, thus contributing to your success. For your applications, we offer the right solutions: Fermentation of microorganisms (bacteria, fungi and yeasts) Cell culture (mammalian cells, insect cells, plant cells and algae) Biofuel (biodiesel and bioethanol) Parallel bioprocesses Custom-made bioreactors and incubation shakers Bioprocess control software Qualification of bioreactors and incubation shakers Closeness to the customer, high quality, innovation and flexibility are our greatest strengths. See for yourself!

InterAx Biotech integrates experimental and computational pharmacology to reveal critical properties of novel GPCR drug candidates. The company is specialized in GPCR drug discovery and covers hit-generation, hit-to-lead and lead optimization for all targets including orphan. InterAx Biotech is a Swiss drug discovery company that focuses on developing drugs targeting disease-specific GPCR heterodimers. The company is pioneering computational pharmacology for drug discovery and has entered into R&D agreements with other organizations for drug development. InterAx Biotech also announced the appointment of seasoned pharmaceutical executive, Mark Levick, MD, Ph.D., as a new board director.

The KD Pharma Group is a CDMO that develops products in the pharmaceutical and nutraceutical space. It is also the worldwide leading producer of API for Omega-3 pharmaceuticals and has built a similar market-leading position in Omega-3 nutraceuticals, formulation and encapsulation services, with over 500 employees and a presence in the UK, Norway, Germany, Switzerland and the US. The KD Pharma Group employs state-of-the-art technology which is protected by numerous patents.

Kenta Biotech is focusing on the discovery and development of innovative, fully human monoclonal antibodies for the treatment of life-threatening hospital infections such as hospital acquired pneumonia. In spite of antibiotic treatment a significant number of patients still die from the infection they acquired at the hospital. Kenta is addressing this significant unmet medical need and has established antigen screening and functional assays for several targets. Kenta's proprietary MabIgX technology combines the advantages of classical hybridoma technology with a unique specific heteromyeloma fusion cell line for the generation and selection of fully human monoclonal antibodies (MAbs). The MabIgX technology allows to harness the most effective antibodies generated by immunocompetent individuals through the isolating and propagation of antigen-specific human B-cells isolated from healthy individuals, actively immunized individuals or from individuals who have successfully defeated an infection caused by the target pathogen. After selection these highly antigen-specific human B-cells are immortalized employing a specific heteromyeloma cell line as fusion partner, which generates stable hybridomas for large scale manufacturing of target specific fully human MAbs. The MabIgX technology does not require any genetic engineering steps or expression systems protected by third party intellectual property rights. The proprietary MabIgX technology platform enables the generation of natural human MAbs with expected superior safety and efficacy profiles. Kenta Biotech currently has one product candidate in clinical development and several product candidates in preclinical development. The lead compound, KBPA 101, is in early Phase II clinical trials in hospital-acquired pneumonia. In 2006, KBPA 101 has received Orphan Drug Status from the EMEA and FDA.

Kuros Biosciences is a biotechnology company that specializes in providing superior biologics for better spinal fusions.

Levitronix® offers low-shear design pumps for sensitive fluids such as cells, LNP's, viral vectors, mRNA/DNA and proteins for the Biotech Industry. The product range includes both single-use and multi-use pumps that enable manufacturing scalability up to 400 L/min. In addition, Levitronix® provides highly accurate inline and clamp-on flow sensors based on non-invasive ultrasound flow sensor technology. Levitronix® consoles and flow control solutions are suitable for precise online blending/mixing and flow control applications.

Limula offers a unique technology supporting routine manufacturing of highly-personalised cell therapies. They provide a modular solution for on-demand cell and gene therapy manufacturing, addressing one of the biggest challenges in the field of medicine.

Loop medical is developing a painless blood collection technology compatible with existing laboratory infrastructure.

LYO-X provides strategic consulting and PK/PD modelling services dedicated to the preclinical and clinical development of biologics and cell based therapies. Our speciality are drug formats at the scientific edge: bi-specifics, antibody-drug conjugates, scFv's, nanobodies and cell based therapies. Whatever your therapeutic approach, we have the expertise in biology, pharmacology, mathematical modeling and drug development to provide tailored support for your unique program. We apply systems pharmacology for target assessment, format selection, compound design, candidate selection, design and analysis of preclinical PK/PD and GLP toxicology studies, first in human dose selection, dose / regimen finding studies and paediatric drug development. Our customers are biotechnology start-ups, pharmaceutical companies and CROs. LYO-X is part of the iBx Network. The iBx Network provides integrated services in toxicology, pharmacology, preclinical and clinical development in combination with modelling and simulation. For more information see www.lyo-x.com

Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 50 countries.

medmix is a global leader in high-precision delivery devices. We occupy leading positions in the healthcare, consumer and industrial end-markets. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 15 production sites worldwide together with our highly motivated and experienced team of over 1'900 employees provide our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). www.medmix.swiss

Metrohm Applikon, headquartered in Schiedam, the Netherlands has been designing, manufacturing and distributing online analytical analyzers worldwide for nearly 50 years. Our industrial process analyzers are now known under the Metrohm Process Analytics brand name. Thousands of these reliable process analyzers perform online or atline analysis for process control with high precisions and uptimes, day in and day out! Our products can be equipped to perform all kinds of analytical methodologies such as: titration, photometry, voltammetry, ion-selective measurement, ion chromatography, and even reagentless NIR spectroscopy. The analyzers are used in a variety of industries like: power, semiconductor, petro/chemical, metal, galvanic, mining, pulp and paper, textile, food and beverages and pharmaceutical industries. For environmental and ambient air applications, dedicated analyzers have been developed and are available. Metrohm Process Analytics offers a wide range of analytical equipment which can be supplied with sample preconditioning systems as well as network software for local or remote data handling and analyzer control. With our well-trained worldwide distributor network, we provide you not only the equipment but also expertise training, startup know-how, and service support afterwards. Most members of this network belong to the Metrohm group of companies. This ensures that our products are supported in application, supply, startup, training, service and supply of spare parts in many countries. Being part of the worldwide Metrohm AG group gives Metrohm Applikon access to a large database of applications for laboratory-based measurements and instrument technology that can also be used as a basis for online applications. Translating a laboratory application to an online application is an almost daily routine, as we have extensive knowledge and experience in both fields.

We are developing real meat - cultivated directly from animal cells ! Our mission is to provide delicious, high quality cultivated meat at a fair price. Better for people, animals and the planet. Our vision is to become a household brand for cultivated meat, thereby accelerating the transition to a global food system that is environmentally, ethically and economically sustainable.

#Nanolive: Capture dynamic, unbiased live cell data to accelerate discovery, development and therapeutics. Nanolive delivers breakthrough 3D imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. Nanolive’s innovative solutions combine screening, imaging and analysis to radically advance how scientists study living cells and provide novel biological insights such as the mechanisms of cancer and neurodegenerative diseases.

To help get better and safer medicines to patients faster. We developed a robust technology and translated it into a unique product which today serves as the gold standard for in vitro testing of products and pharmaceuticals.

Novigenix is a Swiss precision medicine company specialized in ImmunoTranscriptomic solutions for early detection of disease, development of novel therapeutics, and drug target discovery. The Novigenix proprietary LITOSeek™ platform is an AI-enabled RNA analytic platform optimized for mapping the response of the immune system to onset and progression of disease. Our analytical pipelines integrate patient multi-omics data with advanced Machine Learning and artificial intelligence approaches to provide actionable insights and precision solutions. Our liquid biopsy products and services include a suite of biopharma solutions for clinical development of novel therapies, drug target discovery, and early detection of Colorectal Cancer. Novigenix provides services to Pharma and Biotech customers by leveraging the proprietary LITOSeek™ data analytics and patient clinical data platform to deliver previously unknown insights into heterogeneity of patient response and development of actionable biomarkers for optimization of new therapeutic modalities. Specialties Precision Medicine solutions in oncology and immunology, ImmunoTranscriptomics, Machine Learning and Artificial Intelligence, clinical development of multi-omics biomarkers, standardized RNAseq platform and analytic pipelines, product development for In-vitro Diagnostics and Liquid Biopsy solutions.

Nuclidium is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis. Our flexible CuTraceTM platform combines copper radiometals with a variety of highly specific cancer-targeting molecules to rapidly develop novel therapeutic and diagnostic programs. The resulting product portfolio leverages the unique properties of copper to achieve an improved safety and efficacy profile with advantageous economics for hospitals and patients. Nuclidium's differentiated "diagnostic to therapeutic" approach de-risks our development pathway. With innovation as our core, we overcome supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. We are a diverse and interdisciplinary team focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients.

PB&B is a Life Sciences company that specializes in patented injectable technology for remodeling soft tissues of the face and body.

Preclin Biosystems is a biotechnology company that offers a comprehensive in vivo preclinical testing platform for the identification and validation of lead candidate therapeutics.

True precision medicine through single-cell science. Scailyte, a pioneer in AI-driven biomarker discovery from single-cell omics data, has leveraged its proprietary AI platform, ScaiVision, to analyze over 60 million single-cell profiles. The company's extensive network of clinical partners and access to unique patient cohorts in oncology and auto-immunity have led to the development of multiple patent-pending biomarker signatures. Headquartered in Basel, Switzerland, Scailyte collaborates with clinical-stage biotech and pharma companies worldwide, enabling biomarker-driven drug development and paving the way for precision medicine to become a reality. If you want to partner with, reach out to contact@scailyte.com More information about our company, technology & services you can find on our website - https://scailyte.com

Our combined excellence in software development within the field of analytics allows us to drive real advancements in data management. We provide and develop high-quality and innovative vendor-agnostic software solutions that are highly compatible without compromising performance. By automating and digitalizing workflows for generating, analyzing, and utilizing scientific data, we help our customers achieve scientific results faster and more conveniently, enabling better and quicker decision-making.

Sensimed SA, a Swiss company, has developed a unique technology platform on non-invasive soft contact lens-based solution. The first application, the SENSIMED Triggerfish®, provides an automated recording of continuous ocular dimensional change over 24 hours with the aim of revolutionizing glaucoma management enhancing personalization of patient care. The SENSIMED Triggerfish® received the CE mark in 2010 and was approved by the U.S. Food and Drug Administration (FDA) in 2016. Since 2018 the device is registered in Japan at the Pharmaceuticals and Medical Devices Agency (PMDA). Other non-invasive on-eye sensing applications are in development to provide clinically pertinent data with the same continuous monitoring approach. The Company is furthermore focused on expanding the knowledge of how this individual data can best be used in the clinical setting to deliver customized treatment. The data, analysed and modeled on an ongoing basis, is processed in an attempt to identify pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy of treatment. The Company is directly positioned at the convergence between devices, treatment and information. Sensimed believes that with this global knowledge-based approach it will be possible to provide valuable insights that allow ophthalmologists to better understand and treat glaucoma. Sensimed became a subsidiary of SEED CO., Ltd after the acquisition of a majority participation end of 2019.

SGS provides best-in-class contract development, testing, and manufacturing services to deliver high-quality, safe, and effective medicines to market. As a leading contract service organization for over 40 years, we support clients in discovery, clinical development & commercialization, research, product development, quality control testing, and manufacturing. We operate more than 25 worldwide facilities in 11 countries. Our scientific experts accelerate drug development using innovative techniq

SGS is a Switzerland-based testing company that provides services such as supply chain assurance, cybersecurity, metallurgy and brand protection for businesses.

Welcome to SkyCell, the pioneering Swiss company revolutionizing global pharmaceutical logistics by providing cutting-edge temperature-controlled hybrid containers. Powered by data-driven technology, SkyMind the supply chain operating system, optimizes the pharmaceutical supply chain by reducing and predicting the risk of damaging valuable cargo. With an industry-leading temperature excursion rate of less than 0.05% and a profound reduction in CO2 emissions, our innovative approach has been validated by leading pharma companies and trusted by major airlines. As sustainability remains at the core of our values, SkyCell’s reusable hybrid containers cut CO2 pollution by up to 50% and reduce landfill. With every shipment, we are doing our part to save emissions and chart a positive way forward for the pharma industry. Join us on this transformative journey as we revolutionize the pharma supply chain industry through innovation and sustainability. #SkyCell #PharmaLogistics #TemperatureControlledContainers #InnovationInPharma #SustainabilityInTheSupplyChain #SafeSecureSustainable

SmartGene is a bio-informatics application service provider (ASP), delivering secure, integrated, software solutions (SAAS) for the analysis, interpretation and data management of genetic sequences. Customers world-wide use SmartGene’s cloud-based modules for multiple applications, including HIV genotyping/resistance, HCV and Influenza analysis, bacterial and fungal identification, microbiome analysis, strain-typing and molecular epidemiology of viruses and bacteria. SmartGene provides specific medical, clinical research, industrial and epidemiological surveillance applications, designed for routine work-flows, from raw data (Sanger, NGS) to a comprehensive report. Frequently updated quality-controlled reference databases, interpretative algorithms, specifically parameterized bio-informatics tools and customized, searchable sequence databases are integrated within SmartGene’s CE-IVD labeled solutions.

Solvias helps innovative companies advance their path to commercialization with CMC analytical solutions powered by deep scientific expertise and a relentless focus on our customers’ success. With years of expertise in small molecules, biologics and cell and gene therapies, our talented subject matter experts have the know-how, creativity, and tenacity to solve even the most complex analytical challenges. Solvias offers comprehensive solutions from raw materials to drug products to final release testing as well as API development and manufacturing for small molecules. Customers have a single, trusted analytical partner for their entire development journey. Our five global facilities are strategically placed in biopharmaceutical hubs. We are GMP, GLP and ISO certified and conduct over 100 successful customer audits every year. We take pride in putting science and quality at the heart of everything we do, helping our customers bring better and safer products to market faster.

SOPHiA GENETICS is a healthcare company that specializes in genomics analysis using artificial intelligence and data analysis.

Spineart is a privately held medical device company focused on accelerating technology adoption and elevating the standard of spinal care. As a global market leader in spine surgery, we support spine surgeons in over 60 markets worldwide and have introduced unique technologies in the field of minimally invasive surgery, motion preservation, fusion, biologics, fracture treatments, and more. Spineart offers a comprehensive portfolio of procedural solutions and technologies that combine traceable barcoded sterile-packed implants with compact instrument sets, ultimately promoting greater safety, cost-efficiency, and compliance for hospital systems worldwide. Spineart was awarded the "Prix de l'Economie Genevoise 2022" for its contribution to technological and scientific innovations, commercial activities, job creations and ESG principles. Join us as we continue to challenge convention, deliver global expertise, and empower superior care. See open positions at https://www.spineart.com/careers/ This profile is intended for global audiences. For US-specific updates follow our Spineart USA profile.

United for global excellence in dentistry. Every vision has its story, and ours began more than 60 years ago. Since then, our innovations and achievements have become landmarks in dentistry worldwide. Straumann began as a family-owned institute, grew into a publicly-owned holding, and today comprises a number of leading and talented companies around the world. Our vision has always been to create more than just smiles, but lasting confidence for dentists, labs, patients, employees, partners, dental networks and the global community.

ten23 health is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups for the development, manufacture, and testing of tomorrow’s medicines. Our sites in Visp and Basel 🇨🇭 support our clients in developing differentiated, stable, usable, and safe injectable treatments for patients. More about us: www.ten23.health

TissueLabs makes a platform for creating tissues and organs in the lab.

We are one of Europe’s leading suppliers of clinical laboratory testing and medical diagnostic imaging services to private and public healthcare providers, local governments, insurance companies, pharmaceutical companies and the general public. We operate laboratory and medical diagnostic imaging facilities in 14 countries: Czech Republic, Denmark, Finland, France, Italy, Norway, Peru, Portugal, Slovakia, Spain, Sweden, Switzerland, UAE, and the United Kingdom. Our network of facilities provides us with one of the broadest geographic footprints of any clinical laboratory and medical diagnostic services provider in Europe.

Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. The company will celebrate its 40th anniversary in 2024. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies and hospitals as well as under Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. Ypsomed is headquartered in Burgdorf, Switzerland. The company has a global network of production facilities, subsidiaries and distribution partners. Ypsomed has over 2,200 employees worldwide.